Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.
Mustafa BenekliMahmut GumusMetin OzkanFaysal DaneEmin T ElkiranIrfan CicinAlper SevincMehmet AliustaogluAbdurrahman IsikdoganNezih MeydanBerna OksuzogluOzgur OzyilkanMustafa YıldırımFeyyaz OzdemirSadettin KilickapPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Our findings confirm the efficacy and safety profile of TKIs in the first-line treatment of mRCC patients intolerant to cytokine treatment. There was no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS.Trial registration: TURCOS ClinicalTrials.gov Identifier: NCT01585974. Registered April 25, 2012.